PMID- 17982631
OWN - NLM
STAT- MEDLINE
DCOM- 20080123
LR  - 20201226
IS  - 1021-335X (Print)
IS  - 1021-335X (Linking)
VI  - 18
IP  - 6
DP  - 2007 Dec
TI  - HLA-G as a target molecule in specific immunotherapy against renal cell 
      carcinoma.
PG  - 1463-8
AB  - The human leukocyte antigen (HLA)-G molecule can exert immunoregulatory 
      functions. However, its limited tissue distribution and preferential expression 
      in a variety of malignancies suggest the possibility that it could be a target in 
      anti-cancer immunotherapy. In the present study, we tested this possibility by 
      focusing on renal cell carcinoma (RCC) patients, especially those with HLA-A24 
      alleles. Four HLA-G-derived peptides were prepared based on the binding motif to 
      the HLA-A24 alleles. After a stabilization assay confirmed the binding of these 
      peptides to HLA-A24 molecules, they were screened for the capacity to induce 
      peptide-specific cytotoxic T lymphocytes (CTLs) from peripheral blood mononuclear 
      cells (PBMCs) of HLA-A24+ RCC cancer patients. As a result, the HLA-G(146-154) 
      peptide was found to effectively induce peptide-specific CTLs, and HLA-G(146-154) 
      peptide-stimulated PBMCs exhibited cytotoxic activity against HLA-G-expressing 
      HLA-A24+ RCC cells. Antibody blocking and cold inhibition experiments confirmed 
      that the cytotoxicity was partially ascribed to peptide-specific and HLA class 
      I-restricted CD8+ T cells. These results indicate that HLA-G-associated 
      immunoregulation can be overcome and that HLA-G peptide-based anti-cancer 
      immunotherapy is feasible.
FAU - Komohara, Yoshihiro
AU  - Komohara Y
AD  - Cancer Vaccine Development Division, Kurume University Research Center for 
      Innovative Cancer Therapy, Kurume University School of Medicine, Kurume, Japan. 
      ycomo@kumamoto-u.ac.jp
FAU - Harada, Mamoru
AU  - Harada M
FAU - Ishihara, Yuki
AU  - Ishihara Y
FAU - Suekane, Shigetaka
AU  - Suekane S
FAU - Noguchi, Masanori
AU  - Noguchi M
FAU - Yamada, Akira
AU  - Yamada A
FAU - Matsuoka, Kei
AU  - Matsuoka K
FAU - Itoh, Kyogo
AU  - Itoh K
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Greece
TA  - Oncol Rep
JT  - Oncology reports
JID - 9422756
RN  - 0 (HLA Antigens)
RN  - 0 (HLA-A Antigens)
RN  - 0 (HLA-A24 Antigen)
RN  - 0 (HLA-G Antigens)
RN  - 0 (Histocompatibility Antigens Class I)
RN  - 0 (Peptide Fragments)
RN  - 82115-62-6 (Interferon-gamma)
SB  - IM
MH  - Amino Acid Sequence
MH  - Carcinoma, Renal Cell/genetics/*immunology/pathology
MH  - Cell Line, Tumor
MH  - Flow Cytometry
MH  - HLA Antigens/*immunology
MH  - HLA-A Antigens/genetics
MH  - HLA-A24 Antigen
MH  - HLA-G Antigens
MH  - Histocompatibility Antigens Class I/*immunology
MH  - Humans
MH  - Immunotherapy/*methods
MH  - Interferon-gamma/pharmacology
MH  - Kidney Neoplasms/genetics/*immunology/pathology
MH  - Peptide Fragments
MH  - T-Lymphocytes, Cytotoxic/drug effects/immunology
EDAT- 2007/11/06 09:00
MHDA- 2008/01/24 09:00
CRDT- 2007/11/06 09:00
PHST- 2007/11/06 09:00 [pubmed]
PHST- 2008/01/24 09:00 [medline]
PHST- 2007/11/06 09:00 [entrez]
PST - ppublish
SO  - Oncol Rep. 2007 Dec;18(6):1463-8.